Trial
NCT05325281
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Medical College of Wisconsin
Collaborators
Cornerstone Pharmaceuticals; Barbara Ann Karmanos Cancer Institute
Condition
Pancreas Adenocarcinoma
Intervention
CPI-613® (Dose level -1.0 250 mg/m^2)
Why stopped
The pharmaceutical funder pulled funding and no longer plans to develop the drug further.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-12